S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
Log in

ImmuCell Stock Price, Forecast & Analysis (NASDAQ:ICCC)

$5.10
+0.18 (+3.66 %)
(As of 11/21/2019 04:00 PM ET)
Today's Range
$5.10
Now: $5.10
$5.14
50-Day Range
$4.90
MA: $5.17
$5.46
52-Week Range
$4.70
Now: $5.10
$8.28
Volume600 shs
Average Volume7,471 shs
Market Capitalization$36.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.28
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICCC
CUSIPN/A
Phone207-878-2770

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.99 million
Book Value$3.96 per share

Profitability

Net Income$-2,320,000.00

Miscellaneous

Employees47
Market Cap$36.77 million
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable

Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.


ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) announced its earnings results on Monday, August, 12th. The biotechnology company reported ($0.09) earnings per share for the quarter. The biotechnology company had revenue of $2.71 million for the quarter. ImmuCell had a negative net margin of 15.64% and a negative return on equity of 7.35%. View ImmuCell's Earnings History.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for ImmuCell.

Has ImmuCell been receiving favorable news coverage?

Media coverage about ICCC stock has trended somewhat negative on Thursday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ImmuCell earned a daily sentiment score of -1.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for ImmuCell.

Are investors shorting ImmuCell?

ImmuCell saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 4,500 shares, an increase of 80.0% from the September 30th total of 2,500 shares. Based on an average daily trading volume, of 6,900 shares, the short-interest ratio is presently 0.7 days. Currently, 0.1% of the shares of the company are sold short. View ImmuCell's Current Options Chain.

Who are some of ImmuCell's key competitors?

What other stocks do shareholders of ImmuCell own?

Who are ImmuCell's key executives?

ImmuCell's management team includes the folowing people:
  • Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 58)
  • Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
  • Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
  • Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $5.10.

How big of a company is ImmuCell?

ImmuCell has a market capitalization of $36.77 million and generates $10.99 million in revenue each year. ImmuCell employs 47 workers across the globe.View Additional Information About ImmuCell.

What is ImmuCell's official website?

The official website for ImmuCell is http://www.immucell.com/.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]


MarketBeat Community Rating for ImmuCell (NASDAQ ICCC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  187
MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote "Outperform" if you believe ICCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel